Keyphrases
Non-inferiority
100%
Diabetic Foot
100%
Piperacillin-tazobactam
100%
Amoxicillin-clavulanate
100%
Randomized Trial
100%
Empirical Therapy
100%
Treatment Efficacy
40%
Patient's Will
40%
Diabetes Mellitus Type 1
20%
Antipseudomonal
20%
Selection Pressure
20%
Foot Infection
20%
Diabetes Mellitus Type I
20%
Foot Classification
20%
Triple-blind
20%
Clinical Trial Registry
20%
Intravenous Antibiotics
20%
Clinical Support
20%
IV Antibiotics
20%
Collaborative Research
20%
Adult Patients
20%
Pragmatic Clinical Trial
20%
Number of Trials
20%
Hospitalized Adults
20%
Time-to-treatment
20%
Broad-spectrum Antimicrobials
20%
New Zealand
20%
All-cause Mortality
20%
Narrow Spectrum
20%
Good Quality
20%
Diabetic Patients
20%
International Working Groups
20%
Common Complications
20%
Gold Coast
20%
Clinical Practice Guidelines
20%
Australian Guidelines
20%
Readmission
20%
Colonizer
20%
Length of Hospital Stay
20%
Pseudomonas Aeruginosa (P. aeruginosa)
20%
Current Clinical Practice
20%
Antimicrobial Therapy
20%
Usual Care
20%
Optimal Management
20%
Medicine and Dentistry
Diabetes Mellitus
100%
Piperacillin/Tazobactam
100%
Amoxicillin
100%
Clavulanic Acid
100%
Infection
40%
Antibiotics
40%
Primary Outcome
20%
Pathogen
20%
Insulin Dependent Diabetes Mellitus
20%
Antimicrobial Therapy
20%
Preference
20%
Time to Treatment
20%
All Cause Mortality
20%
Clinical Trial
20%
Pseudomonas aeruginosa
20%
Maturity Onset Diabetes of the Young
20%
Patient Care
20%
Pharmacology, Toxicology and Pharmaceutical Science
Clavulanic Acid
100%
Amoxicillin
100%
Diabetes Mellitus
100%
Piperacillin Plus Tazobactam
100%
Antibiotics
40%
Infection
40%
Insulin Dependent Diabetes Mellitus
20%
Clinical Trial
20%
Infectious Agent
20%
Maturity Onset Diabetes of the Young
20%
Preference
20%
Pseudomonas aeruginosa
20%
Antimicrobial Therapy
20%
All Cause Mortality
20%